The components of operating lease cost for the years ended December 31, 2022, 2021 and 2020 were as follows:


	Year ended December 31,		Year ended December 31,		Year ended December 31,
	2022		2021		2020
	(U.S. $ in millions)		(U.S. $ in millions)		(U.S. $ in millions)
Operating lease cost:
Fixed payments and variable payments that depend on an index or rate	$	142	$	135	$	148
Variable lease payments not included in the lease liability		4		4		4
Short-term lease cost		2		2		3

	$	148	$	141	$	155

Supplemental cash flow information related to operating leases was as follows:


	Year ended December 31,		Year ended December 31,		Year ended December 31,
	2022		2021		2020
	(U.S. $ in millions)		(U.S. $ in millions)		(U.S. $ in millions)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	140	$	143	$	151
Right-of-use assets obtained in exchange for lease obligations (non-cash):
Operating leases	$	81	$	81	$	211

Supplemental balance sheet information related to operating leases was as follows:


	December 31,		December 31,
	2022		2021
	(U.S. $ in millions)		(U.S. $ in millions)
Operating leases:
Operating lease ROU assets	$	419	$	495
Other current liabilities		93		109
Operating lease liabilities		349		416
Total operating lease liabilities	$	442	$	525


	December 31,			December 31,
	2022			2021
Weighted average remaining lease term
Operating leases		6.8 years			7.3 years
Weighted average discount rate
Operating leases		5.6	%		5.4	%

Maturities of operating lease liabilities were as follows:


	December 31,
	2022
	(U.S. $ in millions)
202 3		116
202 4		94
202 5		79
202 6		66
202 7 and thereafter		188

Total operating lease payments	$	543

Less: imputed interest		101

Present value of lease liabilities	$	442

In 2020, after obtaining the right to use the building, Teva began transitioning its corporate headquarters to a consolidated site in

Tel-Aviv,

Israel. Teva has an operating lease for the office space in Tel Aviv for an initial term of twelve and a half years, with an option for three extensions. Teva estimates that the reasonably certain holding period of the lease for accounting purposes is twelve and a half years. As of September 30, 2020, upon initial recognition, Teva booked

million as operating lease ROU assets and $

million as operating lease liability.

As of December

31, 2022, Teva’s total finance lease assets and finance lease liabilities were $29 million and $22 million, respectively. As of December 31, 2021, total finance lease assets and finance lease liabilities were $32 million and $25 million, respectively. The difference between those amounts is mainly due to prepaid payments.